113 related articles for article (PubMed ID: 18023381)
1. On the structure, interactions, and dynamics of bound VEGF.
Horta BA; Cirino JJ; de Alencastro RB
J Mol Graph Model; 2008 Apr; 26(7):1091-103. PubMed ID: 18023381
[TBL] [Abstract][Full Text] [Related]
2. Solution structure of a phage-derived peptide antagonist in complex with vascular endothelial growth factor.
Pan B; Li B; Russell SJ; Tom JY; Cochran AG; Fairbrother WJ
J Mol Biol; 2002 Feb; 316(3):769-87. PubMed ID: 11866530
[TBL] [Abstract][Full Text] [Related]
3. Investigating the differential activation of vascular endothelial growth factor (VEGF) receptors.
Horta BA; Sodero AC; de Alencastro RB
J Mol Graph Model; 2009 Oct; 28(3):287-96. PubMed ID: 19734078
[TBL] [Abstract][Full Text] [Related]
4. Dynamical behavior of the vascular endothelial growth factor: biological implications.
Horta BA; Cirino JJ; de Alencastro RB
Proteins; 2007 May; 67(3):517-25. PubMed ID: 17285631
[TBL] [Abstract][Full Text] [Related]
5. Molecular docking and analysis of interactions between vascular endothelial growth factor (VEGF) and SPARC protein.
Chandrasekaran V; Ambati J; Ambati BK; Taylor EW
J Mol Graph Model; 2007 Nov; 26(4):775-82. PubMed ID: 17560152
[TBL] [Abstract][Full Text] [Related]
6. Dynamics of a heparin-binding domain of VEGF(165) complexed with its inhibitor triamterene.
Jeong KW; Lee JY; Lee SA; Yang SP; Ko H; Kang DI; Chae CB; Kim Y
Biochemistry; 2011 Jun; 50(22):4843-54. PubMed ID: 21545128
[TBL] [Abstract][Full Text] [Related]
7. Rational design, structure, and biological evaluation of cyclic peptides mimicking the vascular endothelial growth factor.
Goncalves V; Gautier B; Coric P; Bouaziz S; Lenoir C; Garbay C; Vidal M; Inguimbert N
J Med Chem; 2007 Oct; 50(21):5135-46. PubMed ID: 17900101
[TBL] [Abstract][Full Text] [Related]
8. The comparison of VEGFR-1-binding domain of VEGF-A with modelled VEGF-C sheds light on receptor specificity.
Kasap M; Sazci A
J Theor Biol; 2008 Aug; 253(3):446-51. PubMed ID: 18479712
[TBL] [Abstract][Full Text] [Related]
9. On-resin cyclization of peptide ligands of the Vascular Endothelial Growth Factor Receptor 1 by copper(I)-catalyzed 1,3-dipolar azide-alkyne cycloaddition.
Goncalves V; Gautier B; Regazzetti A; Coric P; Bouaziz S; Garbay C; Vidal M; Inguimbert N
Bioorg Med Chem Lett; 2007 Oct; 17(20):5590-4. PubMed ID: 17826090
[TBL] [Abstract][Full Text] [Related]
10. The C-terminus of viral vascular endothelial growth factor-E partially blocks binding to VEGF receptor-1.
Inder MK; Wise LM; Fleming SB; Mercer AA
FEBS J; 2008 Jan; 275(1):207-17. PubMed ID: 18076652
[TBL] [Abstract][Full Text] [Related]
11. Flexibility of the MHC class II peptide binding cleft in the bound, partially filled, and empty states: a molecular dynamics simulation study.
Yaneva R; Springer S; Zacharias M
Biopolymers; 2009 Jan; 91(1):14-27. PubMed ID: 18767126
[TBL] [Abstract][Full Text] [Related]
12. Heparin-mediated conformational changes in fibronectin expose vascular endothelial growth factor binding sites.
Mitsi M; Hong Z; Costello CE; Nugent MA
Biochemistry; 2006 Aug; 45(34):10319-28. PubMed ID: 16922507
[TBL] [Abstract][Full Text] [Related]
13. Structural basis for the interaction of a vascular endothelial growth factor mimic peptide motif and its corresponding receptors.
Giordano RJ; Anobom CD; Cardó-Vila M; Kalil J; Valente AP; Pasqualini R; Almeida FC; Arap W
Chem Biol; 2005 Oct; 12(10):1075-83. PubMed ID: 16242650
[TBL] [Abstract][Full Text] [Related]
14. Total chemical synthesis of the D2 domain of human VEGF receptor 1.
Goncalves V; Gautier B; Huguenot F; Leproux P; Garbay C; Vidal M; Inguimbert N
J Pept Sci; 2009 Jun; 15(6):417-22. PubMed ID: 19387974
[TBL] [Abstract][Full Text] [Related]
15. C-terminal truncation of Vascular Endothelial Growth Factor mimetic helical peptide preserves structural and receptor binding properties.
Ziaco B; Diana D; Capasso D; Palumbo R; Celentano V; Di Stasi R; Fattorusso R; D'Andrea LD
Biochem Biophys Res Commun; 2012 Jul; 424(2):290-4. PubMed ID: 22749999
[TBL] [Abstract][Full Text] [Related]
16. Relationship between structural flexibility and function in the C-terminal region of the heparin-binding domain of VEGF165.
Jeong KW; Jeong MC; Jin B; Kim Y
Biochemistry; 2013 Dec; 52(49):8823-32. PubMed ID: 24274376
[TBL] [Abstract][Full Text] [Related]
17. Structure-function analysis of the antiangiogenic ATWLPPR peptide inhibiting VEGF(165) binding to neuropilin-1 and molecular dynamics simulations of the ATWLPPR/neuropilin-1 complex.
Starzec A; Ladam P; Vassy R; Badache S; Bouchemal N; Navaza A; du Penhoat CH; Perret GY
Peptides; 2007 Dec; 28(12):2397-402. PubMed ID: 17983687
[TBL] [Abstract][Full Text] [Related]
18. Conformational and dynamics changes induced by bile acids binding to chicken liver bile acid binding protein.
Eberini I; Guerini Rocco A; Ientile AR; Baptista AM; Gianazza E; Tomaselli S; Molinari H; Ragona L
Proteins; 2008 Jun; 71(4):1889-98. PubMed ID: 18175325
[TBL] [Abstract][Full Text] [Related]
19. Insights into activation and RNA binding of trp RNA-binding attenuation protein (TRAP) through all-atom simulations.
Murtola T; Vattulainen I; Falck E
Proteins; 2008 Jun; 71(4):1995-2011. PubMed ID: 18186477
[TBL] [Abstract][Full Text] [Related]
20. VEGF receptor protein-tyrosine kinases: structure and regulation.
Roskoski R
Biochem Biophys Res Commun; 2008 Oct; 375(3):287-91. PubMed ID: 18680722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
